CA2104449A1 - Traitement du cancer oesophagien - Google Patents

Traitement du cancer oesophagien

Info

Publication number
CA2104449A1
CA2104449A1 CA002104449A CA2104449A CA2104449A1 CA 2104449 A1 CA2104449 A1 CA 2104449A1 CA 002104449 A CA002104449 A CA 002104449A CA 2104449 A CA2104449 A CA 2104449A CA 2104449 A1 CA2104449 A1 CA 2104449A1
Authority
CA
Canada
Prior art keywords
hydroxy
course
compound
topotecan
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002104449A
Other languages
English (en)
Inventor
Randall Keith Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2104449A1 publication Critical patent/CA2104449A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002104449A 1991-02-21 1992-02-07 Traitement du cancer oesophagien Abandoned CA2104449A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65893691A 1991-02-21 1991-02-21
US07/658,936 1991-02-21

Publications (1)

Publication Number Publication Date
CA2104449A1 true CA2104449A1 (fr) 1992-08-22

Family

ID=24643326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002104449A Abandoned CA2104449A1 (fr) 1991-02-21 1992-02-07 Traitement du cancer oesophagien

Country Status (8)

Country Link
EP (1) EP0572563A4 (fr)
JP (1) JPH06505487A (fr)
KR (1) KR930702985A (fr)
AU (1) AU664172B2 (fr)
CA (1) CA2104449A1 (fr)
MX (1) MX9200725A (fr)
PT (1) PT100154A (fr)
WO (1) WO1992014470A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6767704B2 (en) 2000-03-27 2004-07-27 Thomas Jefferson University Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression
WO2001066144A2 (fr) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Therapie d'association de medicaments
JP5150909B2 (ja) * 2005-07-27 2013-02-27 オンコセラピー・サイエンス株式会社 食道癌を診断する方法
ES2371171B1 (es) * 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados de camptotecina como agentes antitumorales.
CN102659800B (zh) * 2012-05-11 2014-09-03 中国药科大学 一类低氧激活抗肿瘤化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
EP0572563A1 (fr) 1993-12-08
AU664172B2 (en) 1995-11-09
PT100154A (pt) 1993-05-31
KR930702985A (ko) 1993-11-29
WO1992014470A1 (fr) 1992-09-03
MX9200725A (es) 1992-09-01
JPH06505487A (ja) 1994-06-23
EP0572563A4 (en) 1993-12-29
AU1540692A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
EP0612248B1 (fr) composition contenant le cisplatin et le topotécane comme agent antitumoral
WO2011098539A1 (fr) Traitement de la perte du sens du toucher avec des dérivés de saxitoxine
US5674872A (en) Treatment of ovarian cancer
AU664172B2 (en) Treatment of esophageal cancer
AU2394392A (en) Treatment of colorectal cancer
US5756512A (en) Treatment of non-small cell lung carcinoma
CA2103708C (fr) Traitement du cancer de l'ovaire

Legal Events

Date Code Title Description
FZDE Dead